1229244-86-3

Upstream product

• 905712-38-1 methyl 3-bromo-5-iodo-4-methyl-benzoate 
• 68-12-2 N,N-dimethyl-formamide 
• 1229245-20-8 3-bromo-5-iodo-4-methylbenzoic acid 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 1229245-00-4 methyl 3-bromo-5-[(1E)-3-methoxy-1-propen-1-yl]-4-methylbenzoate 
• 74896-66-5 Methyl 3,5-Dibromo-4-methylbenzoate 

Downstream Products

• 1229244-85-2 methyl 3-bromo-5-(hydroxymethyl)-4-methylbenzoate 
• 1229244-84-1 methyl 3-bromo-5-(iodomethyl)-4-methylbenzoate 
• 1229244-82-9 3-bromo-5-(3-fluorobenzyl)-4-methylbenzaldehyde 
• 1229244-83-0 methyl 3-bromo-5-(3-fluorobenzyl)-4-methylbenzoate 
• 1194488-84-0 N-[3-bromo-5-(3-fluorobenzyl)-4-methylbenzyl]cyclopropanamine 

Relevant academic research and scientific papers

GLUCOSE SENSITIVE INSULIN DERIVATIVES

The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention

GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.

3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS

The present invention relates to 3,4-substituted piperidinyl - based renin inhibitor compounds bearing at 4-position lsoqumolone and having the Formula (I) : The invention further relates to pharmaceutical compositions containing said compounds, as well a